

Index

A

- Acinar-to-ductal metaplasia (ADM), 46–47
- Acute lymphoblastic leukemia (ALL), 86, 176, 301
- Acute myeloid leukemia (AML), 224, 279, 301
- Acute promyelocytic leukemia (APL), 160
- Adeno-associated virus (AAV)
 - base editing, 200
 - CRISPR, 195–197, 200–202, 229
 - nGEMMs, 171–172
- Adenoviruses
 - CRISPR, 196–197, 227
 - nGEMMs, 165, 171–172
- Adult stem cell (ASC), 248–249
- Allograft models. *See* Syngeneic models
- Anillin, 17
- Antimetabolite chemotherapies, 140
- APC mutations
 - base editing, 200
 - in colorectal cancers, 51–52
 - engineered in organoids, 249, 252
 - in prostate cancers, 176
- Autochthonous models, 6, 142, 161, 220–221, 227, 235–238
- Auxin-inducible degrons, 195

B

- Barrett's esophagus, 49–50
- Base editing, 199–200, 233–234
- Biobanks, patient-derived tumor organoid, 257–258
- Bioluminescence imaging (BLI), 292, 295
- Blast crisis chronic myelogenous leukemia (bcCML), 301
- Blood oxygenation level-dependent (BOLD)
 - MRI, 320
- Bone marrow, in vivo imaging of, 298–299
- Bone marrow–liver–thymus (BLT) system, humanized, 273
- Bottlenecks
 - at benign to malignant transition, 34–35
 - during metastasis, 35–36
- BRAF, in lung cancer, 110, 113, 120
- Breast cancer
 - in vivo imaging, 302–303
 - metastasis, 302–303
 - organoids, 256–259
 - patient-derived xenograft (PDX), 275

C

- Cachexia, 147–148
- Cancer-associated fibroblasts (CAFs)
 - cancer progression, role in, 88–90
 - depletion models, 89–90
 - fibroblast activation protein (FAP), 320–321
 - immune system interactions, 90
 - lineage tracing, 88–89
 - in organoids culture, 255
 - origins, 86–88
- Cancer drivers
 - high-throughput functional screen, 219–238
 - nonmutational, 220, 236, 238
- Cancer Gene Consensus database, 220
- Cancer stem cells (CSCs)
 - cell-of-origin distinguished from, 49
 - definition, 54
 - imaging, 299, 303–304
- Carcinogens, and clonal evolution during tumor progression, 30, 33, 35, 37–38
- Cas proteins. *See also* CRISPR
 - Cas13, 236
 - Cas12a, 198, 229–230, 236
 - dCas9 (dead Cas9), 167, 190–191, 198, 231–233
 - high-throughput functional screen, 190–191, 195, 197, 199–200, 202
- Cdkn2a/b*, 34–35
- CDKs, role of, 13–14
- Cell cycle, monitoring
 - classical methods, 15–16
 - cyclin D-CDK4/6, mode of action, 20–21
 - genetic tools to monitor in vivo, 16–18
 - overview, 13–15
 - RB tumor suppressor in genetically engineered mouse models (GEMMs), role of, 18–20
- Cell-cycle checkpoints, 13–14
- Cell division. *See* Cell cycle, monitoring
- Cell line–derived xenograft (CDX), 267, 272
- Cell-of-origin studies
 - cancer stem cells distinguished from, 49
 - colorectal cancer, 51–52
 - esophageal cancer, 49–50
 - liver cancer, 46, 48–49, 53
 - lung cancer, 50–51
 - ovarian cancer, 46, 48, 52–53
 - overview, 43–45
 - pancreas cancer, 45–47, 53

Index

- Cell-of-origin studies (*Continued*)
 - plasticity in, 45–46, 53–54
 - relevance of, 48
 - terminology, 54
 - Cellular plasticity, 45–46, 53–54
 - Cholangiocarcinoma (CCA), 45–49, 51, 53–54, 90–92, 172, 249
 - Chromosomal instability (CIN), in organoids, 249, 253
 - Chromosome engineering, with CRISPR, 197–198
 - Chronic myelogenous leukemia (CML), 119, 301
 - Circulating tumor cells (CTCs), 65–66, 68–70, 75, 115, 275
 - CITE-seq, 234
 - Clinical trials, discrepancies with preclinical therapeutic studies, 120–122
 - Clonal evolution during tumor progression
 - advantages of mouse models for study, 37–38
 - bottleneck at benign to malignant transition, 34–35
 - clonal dynamics of benign and malignant lesions, 33–34
 - genomic evolution, 31, 33
 - immune recognition avoidance, 36–37
 - initiating mutations, 28–29
 - KP model, 30, 34, 36
 - metastasis, 35–36
 - multiple hits principle, 30–32
 - overview, 27–28
 - Clonal sweeps, 34–35
 - CNAs. *See* Copy-number alterations
 - Coclinical trials, patient-derived xenograft (PDX) in, 280, 282
 - CODEX, 236
 - COL171A, 255
 - Collagen and cancer progression, 91
 - Colonization, metastatic, 65–66
 - Colorectal cancer (CRC)
 - cell-of-origin studies, 51–52
 - organoids, 249, 252–253, 255–256, 258–259
 - patient-derived xenograft (PDX), 279
 - Computed tomography (CT)
 - contrast, 312, 316
 - in vivo imaging, 293–294
 - measuring tumor burden, 316–317
 - X-ray CT imaging, 294, 312, 317–318
 - Conditional alleles, 3
 - Contrast agents, 312, 314–315, 318–320
 - Copy-number alterations (CNAs)
 - CRISPR, 197–198
 - defined, 193
 - genomic evolution during tumor progression, 31, 33
 - Cre–LoxP recombination
 - CRISPR integration with, 229–230
 - GEMMs, 43–45
 - historical perspective, 3–4
 - tumor metabolism studies, 148
 - Cre recombinase
 - definition, 192
 - limitations in lineage tracing use, 99
 - non-germline genetically engineered mouse models (nGEMMs), 161–166, 169–174, 180
 - CRISPR
 - advantages and disadvantages of different approaches, 194
 - base editing, 199–200, 233–234
 - chromosome engineering, 197–198
 - components, 190–191
 - Cre/loxP integration with, 229–230
 - diversity of natural systems, 190
 - engineered transplant systems, 201–202
 - ESC-GEMMs, 167, 169
 - germline engineering, 191, 194–195
 - glossary, 192–193
 - high-throughput functional screen, 227–238
 - high-throughput quantitative interrogation of mutations, 202
 - historical perspective on use, 7
 - indels generated by, 167, 170–171, 180, 191–192, 199–201, 231, 237
 - integration with optical phenotyping, 234–235
 - integration with single-cell molecular profiling, 234–235
 - loss-of-function screens, 227–228
 - molecular recording, 203–205
 - next frontier in modeling, 202–205
 - non-germline genetically engineered mouse models (nGEMMs), 161–165, 166–176, 178–180
 - organoids, use in, 249–250, 252
 - overview, 190–191
 - point mutation screens with CRISPR-mediated HDR, 230–231
 - pooled CRISPR screening integration with information-rich analyses, 234–236
 - prime editing, 200–201, 233–234
 - somatic engineering, 195–197
 - CRISPR activation (CRISPRa), 232–233
 - CRISPR-Cas9 system. *See* CRISPR
 - CRISPR-EZ, 195
 - CRISPR interference (CRISPRi), 231
 - CRISPR-READI, 195
 - CSCs. *See* Cancer stem cells
 - CT. *See* Computed tomography
 - CTCs (circulating tumor cells), 65–66, 68–70, 75, 115, 275
 - Cyclin D-CDK4/6, 20–21
 - Cyclin-dependent kinases (CDKs), role of, 13–14
- ## D
- Dead Cas (dCas9), 167, 190–191, 198, 231–233
 - Degradation tags (dTAGs), 195
 - Dendritic cells (DCs)

- depletion models, 97
 - subsets in cancer, 95–97
 - targeting models, 97
 - and tumor immunity, 94–95, 97–98
 - Desmoplasia, 89–90
 - Diffusion, imaging, 318–319
 - Discoidin domain receptors, 91–92
 - Disseminated cancer cells (DICs), 63, 65–66, 72, 74
 - Disseminated tumor cells (DTCs), in vivo imaging of, 303
 - Dissemination, 64–65
 - DMBA/TPA skin carcinogenesis model, 30–31, 33–34, 36
 - DMEM, 149–150
 - DNA integrases, 193, 198, 201
 - Dormancy
 - immune evasion, 74–75
 - invasion-metastasis cascade, 65
 - in vivo imaging studies on, 302–303
 - modeling cancer cell, 72–73
 - tumor dormancy model, 65
 - tumor mass dormancy and the micrometastatic niche, 73–74
 - Double-stranded breaks (DSBs), targeted, 191, 195
 - Driver genes
 - computational prediction of, 220
 - high-throughput functional screen, 219–238
 - Drug development, organoids for, 259
 - Drug resistance, modeling acquired in GEMMs, 118–120
 - Drug targets identification of novel with nGEMMs, 177–178
- E**
- Easi-CRISPR, 195
 - ECM. *See* Extracellular matrix
 - E2F, and cell-cycle monitoring, 16, 19
 - EGF/NOGGIN/R-SPONDIN (ENR), 248
 - EGFR. *See* Epidermal growth factor receptor
 - Electroporation, organ/tissue, 192
 - Electroporation-based non-germline genetically engineered mouse models (EPO-GEMMs), 165, 173–175, 197
 - Endothelial cell
 - in cancer progression and metastasis, 86
 - in cancer progression and therapy responses, 85
 - intercellular signaling with macrophages and cancer cells, 93
 - lineage tracing, 84–85
 - origin in cancer, 84–85, 87
 - plasticity role in cancer progression and therapy, 85
 - Endothelial to mesenchymal transition (EndMT), 85
 - Environmental carcinogens, and clonal evolution, 30, 33, 35, 37–38
 - Epidermal growth factor (EGF), 248
 - Epidermal growth factor receptor (EGFR)
 - knockin models, 190
 - in lung cancer, 110, 113–114, 118–120
 - Epigenetic editing, 233
 - Epistasis, genetic, 219–220
 - EPO-GEMMs, 165, 173–175, 197
 - ESC (embryonic stem cell)-GEMM, 161, 163–169
 - Escherichia coli*, *Pks*⁺, 252–253
 - Esophageal adenocarcinoma (EAC), 49–50
 - Esophageal cancer, cell-of-origin studies
 - on, 49–50
 - EurOPDX Consortium, 278
 - European Bioinformatics Institute (EMBL-EBI), 278
 - Evolution. *See also* Clonal evolution during tumor progression
 - genomic and phenotypic in organoids, 253
 - of mouse models of cancer, 1–7
 - Extracellular matrix (ECM)
 - collagen and cancer progression, 91
 - deposition, signaling, and remodeling in cancer, 90–92
 - desmoplasia, 90
 - glycoproteins contribution to cancer progression and metastasis, 91
 - receptors, 91–92
 - remodeling in cancer, 92
 - Extracellular vesicles, 99–100
- F**
- Fatty acid synthesis, in cancer, 140
 - FDG (fluoro-deoxyglucose), 322
 - Fibroblast activation protein (FAP), 320–321
 - Fibroblasts. *See also* Cancer-associated fibroblasts (CAFs)
 - contribution to cancer progression, 86–90
 - depletion models, 89–90
 - tracing models, 88
 - Field cancerization, 29
 - Flp/FRT recombination
 - conditional GEMMs, 162–163
 - ESC-GEMMs, 166
 - historical perspective, 4
 - in tumor metabolism studies, 148
 - Fluorescence-based in vivo (intravital) imaging, 293, 295–297
 - Fluorescent ubiquitination-based cell-cycle indicator (FUCCI) reporter system, 17–18, 73
 - FOXA1, 249–250
 - FUCCI reporter system, 17–18, 73
- G**
- Gain-of-function (GOF) mutations, 193
 - Gain-of-function (GOF) screens, 231–233

Index

- Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs), 259
- Gene expression, changes in, 220
- Genetically engineered mouse models (GEMMs)
- cancer immunology, 134–135
 - conditional, 160–164, 170
 - constraints, 247–248
 - Cre–LoxP recombination, 43–45
 - definition, 54, 161, 192
 - drug resistance modeling, 118–120
 - early iterations, 160
 - ESC (embryonic stem cell)-GEMM, 161, 163–169
 - historical perspective, 1, 5–7
 - immunotherapy modeling, 116–118
 - limitations of, 162
 - metastasis models, 66–67, 71–72, 76
 - multiple hits in, 30
 - non-germline (*see* Non-germline genetically engineered mouse models [nGEMMs])
 - organoid interactions with, 260–261
 - overview, 159–163
 - for preclinical therapeutic modeling in lung cancer, 109–122
 - tumor metabolism studies, 142, 145, 148
 - tumor microenvironment (TME), 84
- Genome editing. *See* CRISPR
- Genomic evolution during tumor progression, 31, 33
- Genomics, spatially resolved, 235–236
- Germline engineering, with CRISPR, 191, 194–195
- Glucose metabolism, in cancer cells, 139–140, 142–144, 146
- Glutamine, 140
- Glycolysis, 139–140
- Glycoproteins contribution to cancer progression and metastasis, 91
- GONAD, 195
- Graft versus host disease (GVHD), 273
- Guide RNA (gRNA), 190–191, 195, 199–200
- ## H
- Harmonic motion elastography (HME), 320
- Harmonic motion imaging (HMI), 320
- H2B, in lineage tracing, 17–18
- HDR. *See* Homology-directed repair
- HDTV. *See* Hydrodynamic tail vein (HDTV) injection
- Health Insurance Portability and Accountability Act (HIPAA), 268
- Helicobacter pylori*, 252
- Hematological malignancies, in vivo imaging in, 300–301
- Hematopoietic stem and progenitor cells (HSPCs), 298–299, 301
- Hematopoietic stem cells (HSCs), 273
- Hepatocellular carcinoma (HCC), 48, 172–173, 175–178
- HER2 (human epidermal growth factor receptor 2)
- in lung cancer, 110, 114, 119–120
 - in organoids, 259
- HIFs (hypoxia-inducible transcription factors), 70, 74–75, 86
- High-throughput functional screen
- CRISPR-Cas9 loss-of-function screens, 227–228
 - CRISPR interference for gene knockdown screens, 231
 - emerging methods, 231–236
 - future directions, 236–238
 - multiplexed epigenetic editing, 233
 - mutagen-based screens, 221–222
 - overexpression screens, 231–233
 - overview, 220–222
 - point mutation screens with CRISPR-mediated base editing, 233–234
 - point mutation screens with CRISPR-mediated HDR, 230–231
 - pooled CRISPR screening integration with information-rich analyses, 234–236
 - random perturbation screens, 221–225
 - shRNA gene knockdown screens, 225, 227
 - spatially resolved genomics, 235–236
 - targeted combinatorial loss-of-function screens, 228–230
 - targeted single-gene perturbation screens, 225–228
 - transposon-based insertional mutagenesis, 223–224
 - viral genome insertional mutagenesis screens, 222–224
- Historical perspective, on evolution of mouse models, 1–7
- Homology-directed repair (HDR)
- definition, 192
 - knockin allele creation, 195, 197
 - point mutation screens with CRISPR-mediated HDR, 230–231
- Humanized patient-derived xenograft (PDX), 267, 272–274, 277–279, 282
- Human plasma-like medium (HPLM), 149, 151
- Hydrodynamic tail vein (HDTV) injection
- defined, 192
 - nGEMMs, 161, 165, 172–173
 - somatic engineering, 195
- Hypomorphic mutations, 193, 199, 202
- Hypoxia-inducible transcription factors (HIFs), 70, 74–75, 86
- ## I
- Image-seq, 306
- Imaging
- contrast agents, 312, 314–315, 318–320
 - to facilitate coclinical studies, 311–323
 - functional, 312–313
 - immune system and tumor microenvironment, 320–322

- in vivo (*see* In vivo imaging)
 - measuring tumor burden, 316–317
 - overview, 311–316
 - oxygenation, 319–320
 - perfusion and diffusion, 318–319
 - preclinical cancer, 311–323
 - principles and practicalities of modalities, 313–315
 - tissue stiffness, 320
 - tumor metabolism, 321–323
 - Imaging windows, 297–298
 - Immune checkpoint therapies, modeling, 115
 - Immune evasion, dormancy and, 74–75
 - Immune recognition, tumor evolution to avoid, 36–37
 - Immune system
 - cancer-associated fibroblasts (CAFs) interactions, 90
 - evasion of, 74–75
 - imaging, 320–322
 - organoid interactions, 255–256
 - tumor-immune interactions in nGEMMs, 176–177
 - Immunodeficient mouse models, 268, 271–274
 - Immunoediting, 37
 - Immunology, modeling cancer
 - attributes and limitations of approaches, 132
 - GEMMs, 134–135
 - mutagen-induced cancer, 133–134
 - overview, 131–133
 - syngeneic models, 135–136
 - tumor volume plots, 133
 - Immuno-oncology drugs, 133
 - ImmunoPET, 320–321
 - ImmunoSPECT, 320
 - Immunotherapy
 - antitumor murine models, 117
 - modeling in genetically engineered mouse models (GEMMs), 116–118
 - regimen evaluation with non-germline genetically engineered mouse models (nGEMMs), 178
 - Indels (insertions or deletions)
 - with CRISPR, 167, 170–171, 180, 191–192, 199–201, 231, 237
 - definition, 192
 - Initiating mutations, role of, 28–29
 - Institutional Animal Care and Use Committee (IACUC), 268
 - Institutional Biosafety Committee (IBC), 268
 - Integrases, 193, 198, 201
 - Integrins, 91–92
 - Internal Review Board (IRB), 268
 - Intrans paired nicking (ITPN), 252
 - Invasion-metastasis cascade, 64–66
 - In vivo imaging
 - accessing organs/tissues to perform, 297–298
 - applications in biomedical research, 298–299
 - bioluminescence imaging (BLI), 292, 295
 - computed tomography (CT), 293–294
 - fluorescence-based in vivo (intravital) imaging, 293, 295–297
 - future perspectives, 306
 - hematological malignancies, 300–301
 - introduction, 291–292
 - large-volume, high-resolution (LVHR) technique, 305–306
 - limitations, 304–306
 - magnetic resonance imaging (MRI), 292–294, 296
 - metastasis, 301–304
 - normal stem and progenitor cell behavior, 298–300
 - organoids, 304
 - overview of approaches, 292–295
 - positron emission tomography (PET), 293, 295
 - sensitivity, advantages, and disadvantages of techniques, 294–295
 - sequential longitudinal, 299
 - in solid cancers, 301–304
 - ultrasound, 293–294
 - Isocitrate dehydrogenase (IDH), 140–141
- J**
- Jackson Laboratory, 278
- K**
- Ki-67, as cell-cycle marker, 15
 - Knockdown screens
 - CRISPR interference for, 231
 - shRNA gene knockdown screens, 225, 227
 - Knockin alleles, conditional, 3
 - Knockin approaches
 - cell-cycle monitoring, 16–17, 19–20
 - CRISPR, 195
 - GEMMs, 189–190
 - Knockout alleles, conditional
 - CRISPR, 195
 - historical perspective, 3
 - Knockout approaches
 - cell-cycle monitoring, 19–20
 - GEMMs, 189
 - KP model, 30, 34, 36
 - KRAS*
 - engineered mutations in organoids, 249
 - knockin models, 190
 - in lung cancer, 110–113, 118–120
 - single-nucleotide variants (SNVs), 199, 201
 - targeted combinatorial loss-of-function screens, 229
 - and tumor metabolism, 141, 148
- L**
- Large-cell carcinoma (LCC), 50, 110
 - Lentiviruses
 - CRISPR, 195, 202, 227–228
 - nGEMMs, 164, 169–171

Index

- Leucine-rich-repeat-containing G-protein-coupled receptor 5 (LGR5), 248, 252, 255, 259, 299–300, 303–304
- Leukemia
 - acute lymphoblastic leukemia (ALL), 86, 176, 301
 - acute myeloid leukemia (AML), 224, 279, 301
 - acute promyelocytic (APL), 160
 - blast crisis CML (bcCML), 301
 - chronic myelogenous leukemia (CML), 119, 301
 - CRISPR use for transplantable models, 201
 - imaging studies, 299–301
 - murine leukemia virus (MuLV), 222–224
- Lineage plasticity in prostate cancer, 253
- Lineage tracing
 - cancer-associated fibroblasts (CAFs), 88–89
 - clonal dynamics of tumor growth, 33
 - CRISPR use, 203
 - definition, 54
 - endothelial cell, 84–85
 - limitations of Cre-based systems, 99
 - macrophages, 93
 - metastasis, 36, 63
 - in murine cancer models, 43–45
 - using thymidine analogs, 15–17
- Linkage, 193
- Liver cancer
 - cell-of-origin studies, 46, 48–49, 53
 - patient-derived xenograft (PDX), 275
- Lkb1*, 229
- Loss-of-function models, 2–3
- Loss-of-function screens
 - CRISPR-Cas9, 227–228
 - targeted combinatorial, 228–230
- Loss of heterozygosity (LOH) of human leukocyte antigen (HLA) alleles, 37
- Luciferase–luciferin systems, 292
- Lumifluors, 317
- Lung adenocarcinoma (LUAD), 30, 50–51, 110, 112, 114
- Lung cancer
 - cell-of-origin studies, 50–51
 - discrepancies between clinical trials and preclinical therapeutic studies, 120–122
 - drug resistance, modeling acquired in GEMMs, 118–120
 - environmental factors, 115–116
 - human treatment strategies and trials, approaches to mimic, 120–122
 - immunotherapy modeling in GEMMs, 116–118
 - oncogene-targeted therapies, 110–116
 - organoids, 255, 258, 261
 - patient-derived xenograft (PDX), 275
 - preclinical therapeutic modeling, 109–122
- Lung squamous cell carcinoma (LUSC), 51
- M**
- MACHETTE, 197
- Macrophages
 - cancer-associated fibroblast (CAF) origin, 88
 - depletion models, 95
 - imaging with PET, 321
 - intercellular signaling with endothelial cells and cancer cells, 93
 - origins in cancer, 93, 95
 - pleiotropic roles in cancer progression, 92–94, 95 and tumor immunity, 94
 - tumor metastasis, role in, 302
- Magnetic resonance imaging (MRI)
 - blood oxygenation level-dependent (BOLD), 320
 - in vivo imaging, 292–294, 296
 - measuring perfusion and diffusion, 319
 - specialized techniques, 319
- Magnetic resonance spectroscopy (MRS), 316, 322
- Major histocompatibility complex (MHC), 273
- Mass spectrometry imaging (MSI), 146–147
- Matrix-assisted laser desorption/ionization-MSI (MALDI-MSI), 147
- MERFISH, 204
- Metabolism. *See* Tumor metabolism
- Metabolomics, spatial, 146
- Metaplasia, 45–47, 49, 52, 54, 91, 177
- Metastasis
 - bottlenecks during progression, 35–36
 - endothelial cells, role of, 86
 - hypoxia-inducible transcription factors (HIFs), role of, 86
 - invasion-metastasis cascade, 64–66
 - in vivo imaging, 301–304
 - measuring tumor burden, 316–317
 - overview, 63–64
- Metastasis-initiating cells (MICs), 63–64, 66, 73–75
- Metastasis modeling, human-in-mouse
 - approaches for inoculating into circulation, 69
 - organotropic selection, 68–69
 - orthotopic transplantation, 69–70
 - overview, 66–67
 - source of patient cancer cells, 67–68
- Metastasis modeling, mouse-in-mouse
 - GEMMs, 71
 - overview, 71
 - syngeneic allograft models, 71–72
- Metastasis models
 - context-specific tumor–TME interactions, 75–76
 - dormancy, 72–75
 - future directions, 76
 - human-in-mouse, 66–70
 - introducing metastatic cancer cells into mice, 70
 - in vivo, 75–76
 - mouse-in-mouse, 71–72
- Microbiome, of tumor microenvironment, 100
- Microenvironment. *See* Tumor microenvironment (TME)

- Microhomology-mediated end joining pathway (MMEJ), 192
- MICs (metastasis-initiating cells), 63–64, 66, 73–75
- Missense mutations, 193
- MISTRG mice, 273–274
- Molecular profiling, 234–235
- Molecular recording, 203–205
- Mouse embryonic stem cells (mESCs), 192
- Mouse mammary tumor virus (MMTV), 222
- MRI. *See* Magnetic resonance imaging
- MRS (magnetic resonance spectroscopy), 316, 322
- Multiphoton microscopy, 296–297, 299, 302, 305
- Multiple hits principle, 30–32
- Multiplexed epigenetic editing, 233
- Multiplexed in vivo functional genomics, methods for, 221–231
- Murine-derived tumor organoids (MDTOs), 250
- Murine leukemia virus (MuLV), in viral mutagenesis screens, 222–224
- Mutagen-based screens, 221–222
- Mutagen-induced cancer, 133–134
- Mutation order, role of, 220
- MYC*
- in GEMMs, 162, 166, 169, 171–178
 - in lung cancers, 115
 - targeted combinatorial loss-of-function screens, 228
- N**
- Nanolanterns, 317
- Near-infrared fluorescence imaging, 321–322
- Negative selection, 193
- Neoepitopes, 193
- Neurogenesis, 299
- Neutrophil extracellular traps (NETs), 303
- Next-generation surrogate WNT (NGS-WNT), 261
- nGEMMs. *See* Non-germline genetically engineered mouse models (nGEMMs)
- NICHE-seq, 306
- NK cells, induced (iNK), 282
- NOD/SCID mouse strains, 268, 271
- Noggin, 248
- NOG mice, 271, 273, 279
- Non-germline genetically engineered mouse models (nGEMMs)
- accessibility, 179
 - adeno-associated virus (AAV) nGEMMs, 171–172
 - adenoviral, 165, 171–172
 - CRISPR-Cas9-mediated genome editing, 167, 169
 - customizability of production, 168
 - definitions, 161
 - electroporation-based (EPO-GEMM), 165, 173–175
 - ESC (embryonic stem cell)-GEMM, 161, 163–169
 - future of, 180–181
 - GEMMs compared, 161–162, 164–165
 - genetic dependencies in cancer, uncovering, 176
 - historical perspective, 7
 - hydrodynamic tail vein (HDTV)-produced, 161, 165, 172–173
 - identification and validation of genetic drivers in cancer, 175–176
 - immunotherapy regimens, evaluation of, 178
 - informativeness, 179–180
 - insights into cancer biology, 175–177
 - insights into cancer therapy, 177–178
 - lentiviral, 164, 169–171
 - limitations, 180
 - molecularly targeted therapy regimens, evaluation of, 178
 - novel drug targets, identification and validation of, 177–178
 - retroviral, 164, 169
 - shRNA-mediated gene silencing, 166
 - tumor-immune interactions, elucidating, 176–177
 - virally induced, 161, 164–165, 169–172
- Nonhomologous end joining pathway (NHEJ), 192
- Nonobese diabetic (NOD) mice, 268, 271
- Nonsense mutations, 193
- Non-small-cell lung cancer (NSCLC), 50–51
- oncogene-targeted therapies, 110, 114
 - organoids, 255
 - patient-derived xenograft (PDX), 271
 - tumor metabolism, 141–142
- NSG mice, 271, 273
- Nude mice, 268, 271
- O**
- Occupational Safety and Health Administration (OSHA), 268
- Oncogenes, and metabolic pathway regulation, 140
- Oncogene-targeted therapies, for lung cancer, 110–116
- Optical phenotyping, 234–235
- Optical reporter, 312, 316
- ORF (open reading frame) screens, 231
- Organoids
- applications in basic cancer research, 249–256
 - applications in translational cancer research, 250, 256–259
 - benefits and limitations, 160
 - breast cancer, 256–259
 - cancer immunology, 137
 - colorectal cancer (CRC), 249, 252–253, 255–256, 258–259
 - CRISPR use, 201–202, 249–250, 252
 - derivation, 248–249
 - GEMMs interactions with, 260–261
 - genomic and phenotypic evolution in, 253–254
 - historical perspective, 5–7
 - in vivo imaging, 304
 - metastasis models, 68–69, 72

Index

- Organoids (*Continued*)
 minimal modeling of microenvironmental interactions, 254–256
 modeling cancer initiation and progression, 249–253
 next-generation modeling of cancer, 247–262
 overview, 247–249
 prostate cancer, 249–250, 253–254, 259, 261
 regenerative, 249
 types and notable biobanks, 257–258
 xenografting to study in vivo aspects of cancer, 256
- Ovarian cancer
 cell-of-origin studies, 46, 48, 52–53
 patient-derived xenograft (PDX), 279
- Overexpression screens, 231–233
- Oxygenation, imaging, 319–320
- P**
- p53*
 metabolic effects of loss, 140, 148
 targeted combinatorial loss-of-function screens, 229
- PAM (protospacer-adjacent motif), 191–192, 199, 204
- Pancreatic cancer
 cell-of-origin studies, 45–47, 53
 in vivo imaging, 305
- Pancreatic ductal adenocarcinoma (PDAC)
 cell–cell interactions within tissues, 145–146
 cell-of-origin studies, 45–47
 cellular plasticity, 53
 in vivo imaging, 303
 in KP mice, 30
 metabolism, 141, 148
 metastasis, 36
 nGEMM studies, 169, 171, 174
 organoids culture, 255
 patient-derived xenografts (PDXs), 271, 279
 subtype identification, 255
- Pancreatic intraepithelial neoplasia (PanINs), 46–47
- Pancreatic neuroendocrine (NE) tumors (PNETs), 46–47
- Pathfinder* web portal, 278
- Pathogen-associated molecular patterns (PAMPs), 131
- Patient-derived organoid (PDO)
 historical perspective, 5–7
 lung cancer models, 115
 metastasis models, 68–69
- Patient-derived tumor organoid (PDTO)
 biobanks, 257–259
 chromosomal instability, 253
 GEMMS interactions with, 261
- Patient-derived xenograft (PDX)
 benefits and limitations, 160
 challenges, 277–279
 clinical and laboratory infrastructure, 268–269
 in coclinical trials, 280, 282
 constraints, 247–248
 CRISPR use, 201
 engraftment, characterization, and annotation, 275–277
 high-throughput functional screen, 220–221
 historical perspective, 5–6
 humanized, 267, 272–274, 277–279, 282
 immunodeficient mice, 268, 271–274
 limitations, 267, 273, 277–279, 282
 lung cancer models, 115
 metastasis models, 66, 68
 milestones in development, 270
 multi-omic analyses, 277
 overview, 267
 in personalized medicine, 281–282
 preclinical medicine, use in, 279, 282
 regulatory requirements, 268
 Patient-derived tumor xenograft (PDTX), 247
 Pattern recognition receptors (PRPs), 131
 PDAC. *See* Pancreatic ductal adenocarcinoma
 PDCM Finder, 278
 PDO. *See* Patient-derived organoid
 PDTO. *See* Patient-derived tumor organoid
 PDTX. *See* Patient-derived tumor xenograft
 PDX. *See* Patient-derived xenograft
 PDXNet portal, 278
 pegRNA, 200, 202
 Perfusion, imaging, 318–319
 Peripheral blood mononuclear cells (PBMCs), 272–273
 Personalized medicine, patient-derived xenograft (PDX) in, 281–282
 PET. *See* Positron emission tomography
 Phosphoglycerate dehydrogenase (PHGDH), 140
 Phosphohistone H3 (PH3), as cell-cycle marker, 15–16
 PiggyBac, 224
 PIK3CA mutations, 249
 Plasmix, 149, 151
 Plasticity, in cell-of-origin studies, 45–46, 53–54
 Point mutation screens with CRISPR-mediated base editing, 233–234
 Positive selection, 193
 Positron emission tomography (PET)
 immunoPET, 320–321
 in vivo imaging, 293, 295
 of oxygenation, 320
 of perfusion and diffusion, 318–319
 Precision oncology, 189
 Preclinical therapeutic modeling
 discrepancies with clinical trials, 120–122
 overview, 109
 Prime editing, 200–201, 233–234
 Prostate cancer
 castration-resistant (CRPC), 250, 253–254
 lineage plasticity, 253
 organoids, 249–250, 253–254, 259, 261
 Protospacer-adjacent motif (PAM), 191–192, 199, 204

- Protospacer sequence, 190
Pten (Phosphatase and TENsin) loss-of-function models, 3
- R**
- Radon, modeling exposure to, 115–116
 Random perturbation screens
 considerations and opportunities, 224–225
 mutagen-based screens, 221–222
 transposon-based insertional mutagenesis, 223–224
 viral genome insertional mutagenesis screens, 222–224
RAS, in targeted combinatorial loss-of-function screens, 228
RB1
 knockout GEMMs, 189
 lineage plasticity in prostate cancer, 253
 loss-of-function models, 2–3
 RB tumor suppressor
 in cell-cycle monitoring, 18–20
 in genetically engineered mouse models (GEMMs), role of, 18–20
 Recombinase-mediated cassette exchange (RMCE), 166
 Rectal cancer organoids, 256
 Renal cancer organoids, 259
 Retroviral nGEMMs, 164, 169
 RIP-TAG model, 2, 43
 Roof plate-specific spondin (R-SPONDIN), 248–249
 RPMI, 149–150
- S**
- Seed and soil hypothesis, 65
 Separation-of-function mutations, 193
 Serine, 140
 Serum-like modified eagle’s medium (SMEM), 149
 Severe combined immune deficiency (SCID) mice, 268, 271
 SHARE-seq, 234
 shRNA gene knockdown screens, 225, 227
 shRNA-mediated gene silencing, 166
 Single-cell molecular profiling, 234–235
 Single-cell RNA sequencing (scRNA-seq), 203, 234, 256
 Single-cell technologies, historical perspective on use, 7
 Single-nucleotide variants (SNVs)
 base editing, 199–200
 CRISPR, 198–202
 definition, 193
 genomic evolution during tumor progression, 31, 33
 Single-photon emission CT, 295
 Sleeping Beauty, 224
 Slide-seq, 236
SMAD, 249
 Small-cell lung cancer (SCLC)
 cellular origins, 50–51
 oncogene-targeted therapies, 110, 112, 114–115, 120
 Smoking-related lung cancer, modeling, 115
 SNVs. *See* Single-nucleotide variants
 Sodium iodide symporter (NIS), 317
 Solid cancers, in vivo imaging of, 301–304
 Somatic engineering, with CRISPR, 195–197
 Spatially resolved genomics, 235–236
 Spatial metabolomics, 146
 Stable isotope metabolite labeling, 141–145
 Standard operating procedures (SOPs)
 Stem cells. *See also* Cancer stem cells
 adult (ASC), 248–249
 hematopoietic (HSCs), 273
 hematopoietic stem and progenitor cells (HSPCs), 298–299, 301
 in vivo imaging, 298–300
 mouse embryonic (mESCs), 192
 SV40T antigen, 2, 43
 Syngeneic models
 benefits and limitations, 160
 cancer immunology, 135–136
 metastasis modeling, 71–72
- T**
- Targeted combinatorial loss-of-function screens, 228–230
 Targeted single-gene perturbation screens
 considerations and opportunities, 228
 CRISPR-Cas9 loss-of-function screens, 227–228
 shRNA gene knockdown screens, 225, 227
 TCA (tricarboxylic acid) cycle, in tumor metabolism, 140, 142, 147, 149
 T-cell receptor (TCR), 132, 136
 Tetracycline-related systems, 4
 Therapy
 immunotherapy modeling in GEMMs, 116–118
 molecularly targeted regimen evaluation with nGEMMs, 178
 novel drug target identification with nGEMMs, 177–178
Thosea asigna virus 2A (T2A), 17
 Thymidine analogs, lineage tracing using, 15–17
 Tissue stiffness, imaging, 320
 TME. *See* Tumor microenvironment
TP53
 engineered mutations in organoids, 249
 knockout GEMMs, 189
 lineage plasticity in prostate cancer, 253
 single-nucleotide variants (SNVs), 199
TP63, 250
 Transitions, 193
 Transposon-based insertional mutagenesis, 223–224
 Transversions, 193
 Treatment strategies and trials, approaches to mimic, 120–122
 Tricarboxylic acid (TCA) cycle, in tumor metabolism, 140, 142, 147, 149

Index

- Trp53*
base editing, 200
loss in DMBA/TPA skin carcinogenesis model, 34–35
loss-of-function models, 2–3
single-nucleotide variants (SNVs), 199, 201
targeted combinatorial loss-of-function screens, 229
- Tuba-seq, 202
- Tumor burden, measuring, 316–317
- Tumor dormancy model, 65
- Tumor immunity
dendritic cells (DCs), 94–95, 97–98
macrophages, 94
- Tumor interstitial fluid (TIF), 149–150
- Tumor metabolism
cell–cell interactions within tissues, 145–147
imaging, 321–323
overview, 139–141
physiological media mimicking nutrient levels in TME, 149–151
stable isotope metabolite labeling, 141–145
studying metabolic relationships between tissues, 147–149
- Tumor microenvironment (TME)
context-specific tumor–TME interactions, 75–76
dendritic cells (DCs) and tumor immunity, 94–98
endothelial cell origin in cancer, 84–85, 87
extracellular matrix deposition, signaling, and remodeling, 90–92
extracellular vesicles, 99–100
fibroblast contribution to cancer progression, 86–90
future considerations, 98–100
imaging, 320–322
intercellular signaling between macrophages, endothelial cells, and cancer cells, 93
macrophage roles in cancer progression, 92–95
microbiome, 100
minimal modeling of microenvironmental interactions in organoids, 254–256
overview, 83–84
physiological media mimicking nutrient levels in, 149–151
- Tumor microenvironment of metastasis (TMEM)
doorways, 302
- Tumor progression
cancer-associated fibroblasts (CAFs), role of, 88–90
clonal evolution during, 27–28
genomic evolution during, 31, 33
- Tumor suppressor genes
historical perspective, 2–4
metabolic pathway regulation, 140
- Tumor volume plots, 133
- ## U
- Ultrasound imaging
in vivo, 293–294
measuring tumor burden, 316
- Uninterrupted growth model, 65
- ## V
- Viral genome insertional mutagenesis screens, 222–224
- Virus-like particles (VLPs), 192, 196–197, 200, 202
- ## W
- Warburg effect, 139
- WNT
next-generation surrogate (NGS-WNT), 261
signaling in organoids, 248–249, 258–259, 261
- ## X
- Xenograft models
benefits and limitations, 160
cell line–derived xenograft (CDX), 267, 272
historical perspective, 5–7
metastasis models, 66–67, 69–71, 75
tumor metabolism studies, 142
- X-ray CT imaging, 294, 312, 317–318